Skip to main content
. 2024 Feb 20;12(3):470. doi: 10.3390/biomedicines12030470

Figure 1.

Figure 1

NSL-YHJ-2-27 suppresses the viability of breast cancer cells. After treatment of cells with the indicated concentrations of NSL-YHJ-2-27 (0, 0.5, 1, 2, 5, 10, 20, and 50 µM), resazurin reduction assay was performed to determine the viability of the cells. (A,B) Cell viabilities were plotted against varying concentrations of NSL-YHJ-2-27 expressed as the percentage of fluorescence intensity compared to the controls. (C) EC50 values for the effects of the treatments on cell viability.